PMID- 37950414
OWN - NLM
STAT- MEDLINE
DCOM- 20240312
LR  - 20240312
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 47
IP  - 2
DP  - 2024 Mar
TI  - Depletion of tilmicosin residue in Gushi chickens following oral administration 
      via drinking water.
PG  - 114-120
LID - 10.1111/jvp.13416 [doi]
AB  - This study aimed to examine the depletion of tilmicosin residues in Gushi 
      chickens following the administration at a concentration of 75 mg/L in their 
      drinking water for three consecutive days. Plasma, liver, kidney, lung, muscle, 
      and skin + fat samples were collected from 6 chickens at 6 h, 1, 3, 5, and 7 days 
      after the treatment. Tilmicosin concentrations in the samples were determined 
      using a high-performance liquid chromatography (HPLC) method. The findings 
      revealed that the highest tilmicosin residues were detected in the liver, 
      followed by the kidney, lung, skin + fat, muscle, and plasma. Notably, at 7 days 
      post-treatment, no drug residue was detected in all samples except for the liver 
      and kidney. The non-compartmental model was employed to calculate relevant 
      pharmacokinetic parameters. The elimination half-lives (t(1/2lambdaz) ) of tilmicosin 
      were as follows, ranked from long to short: skin + fat (45.42 h), liver 
      (44.17 h), kidney (40.06 h), plasma (37.64 h), lung (31.39 h), and muscle 
      (30.05 h). Considering the current residue depletion and the maximum residue 
      limits (MRLs) set by Chinese regulatory authorities, the withdrawal times for 
      tilmicosin were estimated as 18.91, 10.81, and 8.58 days in the kidney, liver, 
      and skin + fat, respectively. A rounded-up value of 19 days was selected as the 
      conclusive withdrawal time. Furthermore, based on the observed tilmicosin 
      concentrations in plasma and lung, combined with previously reported minimum 
      inhibitory concentration (MIC) values against Mycoplasma gallisepticum, the 
      current dosing regimen was deemed adequate for treating Mycoplasma gallisepticum 
      infections in Gushi chickens.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Zhang, Mei
AU  - Zhang M
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
FAU - Qian, Kun
AU  - Qian K
AD  - Tianjin Agricultural Ecological Environment Monitoring and Agricultural Product 
      Quality Testing Center, Tianjin, China.
FAU - Li, Guang-Hui
AU  - Li GH
AD  - Shantou Customs District Technology Center, Shantou, China.
FAU - Duan, Ming-Hui
AU  - Duan MH
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
FAU - Li, Ze-En
AU  - Li ZE
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
FAU - Dai, Yan
AU  - Dai Y
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
FAU - Chen, Jun-Cheng
AU  - Chen JC
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
FAU - Yang, Fan
AU  - Yang F
AD  - College of Animal Science and Technology, Henan University of Science and 
      Technology, Luoyang, China.
LA  - eng
GR  - Foundation for the University Young Key Teacher Program of Henan Province/
GR  - Natural Science Foundation of Henan Province/
PT  - Journal Article
DEP - 20231110
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - XL4103X2E3 (tilmicosin)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Drinking Water)
RN  - YEF4JXN031 (Tylosin)
SB  - IM
MH  - Animals
MH  - *Anti-Bacterial Agents
MH  - *Drinking Water
MH  - Chickens
MH  - Administration, Oral
MH  - Tylosin/*analogs & derivatives
OTO - NOTNLM
OT  - Gushi chickens
OT  - backyard chickens
OT  - depletion
OT  - tilmicosin
OT  - withdrawal time
EDAT- 2023/11/11 11:46
MHDA- 2024/03/12 06:42
CRDT- 2023/11/11 01:03
PHST- 2023/10/22 00:00 [revised]
PHST- 2023/09/04 00:00 [received]
PHST- 2023/10/26 00:00 [accepted]
PHST- 2024/03/12 06:42 [medline]
PHST- 2023/11/11 11:46 [pubmed]
PHST- 2023/11/11 01:03 [entrez]
AID - 10.1111/jvp.13416 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2024 Mar;47(2):114-120. doi: 10.1111/jvp.13416. Epub 2023 
      Nov 10.